Myriad Genetics ($MYGN) paid $270 million for Crescendo Bioscience in February and isn't wasting any time promoting the accomplishments of its now wholly owned subsidiary. According to the company, a new study affirms the clinical viability of Crescendo's Vectra DA, a protein-based test designed to assess a patient's rheumatoid arthritis disease progression and activity. The trial took place in Sweden involving 235 patients with early-stage rheumatoid arthritis who hadn't taken a prescribed treatment yet. Myriad/Crescendo said the data shows the test's usefulness as helping to determine more personalized treatments. Details are published online in the journal Annals of the Rheumatic Diseases. Release | Abstract